Takeda Historical Financial Ratios
TAK Stock | USD 13.57 0.13 0.97% |
Takeda Pharmaceutical is promptly reporting on over 122 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 4.9 K, Free Cash Flow Yield of 0.032, Invested Capital of 0.0 or Operating Cash Flow Per Share of 481 will help investors to properly organize and evaluate Takeda Pharmaceutical financial condition quickly.
Takeda |
About Takeda Financial Ratios Analysis
Takeda PharmaceuticalFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Takeda Pharmaceutical investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Takeda financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Takeda Pharmaceutical history.
Takeda Pharmaceutical Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Takeda Pharmaceutical stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Takeda Pharmaceutical sales, a figure that is much harder to manipulate than other Takeda Pharmaceutical Co multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is Takeda Pharmaceutical Co dividend as a percentage of Takeda Pharmaceutical stock price. Takeda Pharmaceutical dividend yield is a measure of Takeda Pharmaceutical stock productivity, which can be interpreted as interest rate earned on an Takeda Pharmaceutical investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Most ratios from Takeda Pharmaceutical's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Takeda Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. At this time, Takeda Pharmaceutical's ROIC is quite stable compared to the past year. Net Income Per Share is expected to rise to 138.75 this year, although the value of Free Cash Flow Yield will most likely fall to 0.03.
2021 | 2022 | 2024 (projected) | Dividend Yield | 0.0519 | 0.0414 | 0.0463 | Price To Sales Ratio | 1.53 | 1.68 | 1.45 |
Takeda Pharmaceutical fundamentals Correlations
Click cells to compare fundamentals
Takeda Pharmaceutical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Takeda Pharmaceutical fundamentals Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Price To Sales Ratio | 3.42 | 1.57 | 1.95 | 1.53 | 1.68 | 1.45 | |
Dividend Yield | 0.0549 | 0.0455 | 0.0519 | 0.0414 | 0.0441 | 0.0463 | |
Ptb Ratio | 1.09 | 1.2 | 0.96 | 1.06 | 0.89 | 0.85 | |
Days Sales Outstanding | 87.05 | 92.76 | 74.08 | 61.78 | 59.72 | 95.78 | |
Book Value Per Share | 3.0K | 3.3K | 3.6K | 4.1K | 4.6K | 4.9K | |
Free Cash Flow Yield | 0.0878 | 0.12 | 0.17 | 0.0509 | 0.0362 | 0.032 | |
Operating Cash Flow Per Share | 430.1 | 647.2 | 718.33 | 629.69 | 457.89 | 480.78 | |
Stock Based Compensation To Revenue | 0.008848 | 0.0118 | 0.0122 | 0.0151 | 0.0166 | 0.00912 | |
Pb Ratio | 1.09 | 1.2 | 0.96 | 1.06 | 0.89 | 0.85 | |
Ev To Sales | 2.92 | 3.09 | 2.51 | 2.63 | 2.55 | 2.43 | |
Free Cash Flow Per Share | 290.29 | 495.81 | 599.34 | 221.33 | 150.61 | 137.24 | |
Roic | (0.007456) | 0.0533 | 0.035 | 0.0386 | 0.0483 | 0.0778 | |
Inventory Turnover | 1.43 | 1.32 | 1.3 | 1.26 | 1.18 | 1.12 | |
Net Income Per Share | 28.41 | 240.72 | 147.14 | 204.29 | 92.09 | 138.75 | |
Days Of Inventory On Hand | 254.42 | 276.74 | 281.35 | 289.42 | 308.49 | 154.43 | |
Payables Turnover | 5.15 | 4.28 | 3.74 | 4.05 | 4.47 | 5.04 | |
Capex To Revenue | 0.0661 | 0.0739 | 0.0521 | 0.16 | 0.11 | 0.12 | |
Cash Per Share | 419.62 | 642.01 | 559.64 | 356.81 | 302.27 | 287.16 | |
Pocfratio | 7.69 | 6.16 | 4.87 | 6.91 | 9.08 | 8.63 | |
Interest Coverage | 0.61 | 2.05 | 2.77 | 2.89 | 1.39 | 1.32 | |
Payout Ratio | 1.31 | 6.39 | 0.75 | 0.88 | 1.99 | 2.09 | |
Capex To Operating Cash Flow | 0.33 | 0.23 | 0.17 | 0.65 | 0.67 | 0.7 | |
Pfcf Ratio | 11.4 | 8.04 | 5.84 | 19.65 | 27.62 | 36.51 | |
Days Payables Outstanding | 70.88 | 85.2 | 97.59 | 90.2 | 81.58 | 106.91 | |
Income Quality | 15.12 | 2.69 | 4.88 | 3.08 | 4.97 | 5.22 | |
Roe | 0.009366 | 0.0727 | 0.0405 | 0.0499 | 0.0198 | 0.0188 | |
Ev To Operating Cash Flow | 14.34 | 9.79 | 7.98 | 10.85 | 15.21 | 14.45 | |
Pe Ratio | 116.44 | 16.55 | 23.77 | 21.29 | 45.16 | 33.62 | |
Return On Tangible Assets | 0.00954 | 0.0757 | 0.0465 | 0.0647 | 0.0266 | 0.0252 | |
Ev To Free Cash Flow | 21.25 | 12.77 | 9.57 | 30.86 | 46.23 | 35.59 | |
Earnings Yield | 0.008588 | 0.0604 | 0.0421 | 0.047 | 0.0221 | 0.0299 | |
Net Debt To E B I T D A | 5.06 | 3.73 | 2.95 | 3.25 | 5.01 | 5.27 | |
Current Ratio | 1.21 | 1.13 | 1.53 | 0.97 | 1.11 | 1.05 | |
Tangible Book Value Per Share | (2.2K) | (1.8K) | (1.6K) | (1.7K) | (1.5K) | (1.5K) | |
Receivables Turnover | 4.19 | 3.93 | 4.93 | 5.91 | 6.11 | 3.47 | |
Graham Number | 1.4K | 4.2K | 3.5K | 4.3K | 3.1K | 1.8K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.049 | Dividend Share 192 | Earnings Share 0.59 | Revenue Per Share 1.4 K | Quarterly Revenue Growth 0.127 |
The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.